Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals Ltd.

Overview
Date Founded

2003

Headquarters

2 Holzman Street,Weizmann-Science Park,Rehovot, HaMerkaz 76704

Type of Company

Public

Employees (Worldwide)

81

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services

Company Description

Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.

Contact Data
Trying to get in touch with decision makers at Foamix Pharmaceuticals Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

General Counsel & Chief Legal Officer

Chief Commercial Officer

Chief Scientific Officer

Chief Financial Officer & Country Manager

Finance Director

Executive Vice President, Intellectual Property

Senior Vice President, Pharmaceutical Development

Senior Vice President, Global Human Resources

Vice President, Regulatory Affairs

Board of Directors

Chief Executive Officer at FuturaGene Ltd.

Managing Partner at Alnitak Capital LLC

Managing Partner at Primary I-Research LLC

Chief Executive Officer at Foamix Pharmaceuticals Ltd.

Former Head-Innovative Ventures at Teva Pharmaceutical Industries Ltd.

Former General Counsel at Warner Chilcott Ltd.

Director-Northern California Chapter at The Association of Bioscience Financial Officers

President & Chief Executive Officer at Seabright Associates, Inc.

Managing Partner at Jerusalem Global Ventures Ltd.

Paths to Foamix Pharmaceuticals Ltd.
Potential Connections via
Relationship Science
You
Foamix Pharmaceuticals Ltd.
Owners & Shareholders
Details Hidden

Perceptive Advisors focuses on investment opportunities in healthcare, with an emphasis on biotechnology. The firm believes that significant opportunities exist in biotechnology due to pervasive underlying market inefficiencies and volatility. Perceptive Advisors advises two separate master-feeder private fund structures.The Perceptive Life Sciences Funds invest in the equities of growth healthcare companies and value plays, with an emphasis on biotechnology. Perceptive Advisors seeks to identify opportunities to exploit relative value disparities and inefficiencies that exist on both the long and short side of the market. They focus on a universe of about 300 smaller, more inefficiently priced companies which are underfollowed by Wall Street biotechnology analysts. Hedging strategies using long and short equity positions, equity options, and index options are used in an attempt to reduce and control risk.The Perceptive Credit Opportunity Fund seeks to achieve superior risk-adjusted returns by investing in senior secured loans and other debt and debt-related instruments issued by small- and mid-cap publicly traded companies and privately-held emerging growth companies primarily in the healthcare and related industries. The fund's investments may be originated by the fund or in collaboration with a syndicate of other credit investors. Most of the fund's investments will be structured as directly originated loans to healthcare companies.Perceptive Advisors also advises two separate accounts. The investment strategies of the separate accounts are substantially similar to those of the Perceptive Life Sciences Fund, though the separate accounts may take more concentrated positions and use a higher degree of leverage.

Details Hidden

DCS Advisors primarily uses a fundamental valuation analysis for all long and short positions. They may consider, among other things, analyses of income, balance sheets and cash flow statements, capital structure management, industry, competitors and competitive position, public and private market valuation, and contingent liabilities. The firm applies their fundamental value orientation opportunistically across a range of companies and industries. DSC seeks to diversify investment holdings in order to limit portfolio correlation. While they mainly rely on fundamental valuation analysis, DSC may take a macro view or other view when selecting investments.DSC's main investment strategy focuses on acquiring long positions in undervalued securities or selling short overvalued securities. On the long side, the firm targets companies where an investment has limited downside and compelling appreciation potential. Companies in which they invest tend to have the following characteristics: an attractive valuation in absolute terms and/or with regard to growth prospects; a sustainable business model with opportunities to maintain or grow their business and operating margins; solid management and strong earnings quality; the ability to generate cash flow even in recessionary or distressed environments; reasonably assessable contingent or off balance sheet liabilities; and low risk of obsolescence. On the short side, DSC targets companies with few or none of these characteristics. In addition, DSC seeks investments that appear to be overvalued due to additional specific or industry-wide short term or sustained business flaws.DSC may use of a variety of securities, including, but not necessarily limited to, equities, options, fixed-income securities, bank debt, warrants, and derivative contracts such as total return swaps on equities or bank debt, credit default swaps, and/or swaptions. The firm may employ leverage and/or invest in illiquid securities such as private placements. DSC seeks to hedge certain risks and exposures associated by investing in derivatives, including equity index option or equity options on individual securities contracts, or through long positions which mitigate or limit portfolio exposure. They may also hedge foreign currency exposure for investments denominated in non-US Dollars.

Details Hidden

Great Point Partners seeks to achieve positive excess returns by investing in publicly traded biotechnology, healthcare information technology, medical device, medical diagnostic and specialty pharmaceutical companies. The firm focuses on creating a balanced portfolio comprised primarily of companies that are undervalued by the public markets. Great Point's hedge funds employ a bottom-up research-driven approach to investing in the securities of undervalued, publicly-traded healthcare companies. They target fast-growing, technology- driven small-cap companies. In addition, Great Point manages private equity funds that invest in private, primarily profitable, lower middle-market, growing healthcare companies.

Recent Transactions
Details Hidden

Foamix Pharmaceuticals Ltd. issued USD Ordinary Shares

Details Hidden

Foamix Pharmaceuticals Ltd. issued Ordinary Shares

Details Hidden

Foamix Pharmaceuticals Ltd. issued Ordinary Shares

Transaction Advisors
Underwriter

Advised onFoamix Pharmaceuticals Ltd. issued USD Ordinary Shares

Underwriter

Advised onFoamix Pharmaceuticals Ltd. issued USD Ordinary Shares

Escrow Agent

Advised onFoamix Pharmaceuticals Ltd. issued USD Ordinary Shares

Managing Director

Advised onFoamix Pharmaceuticals Ltd. issued USD Ordinary Shares

Managing Director, ECM

Advised onFoamix Pharmaceuticals Ltd. issued USD Ordinary Shares

Underwriter

Advised onFoamix Pharmaceuticals Ltd. issued USD Ordinary Shares

Advisors & Consultants
Publicist

Founding Partner at LifeSci Capital LLC

Consultant

Former General Counsel at Warner Chilcott Ltd.

Consultant

Clinical Professor of Dermatology at NYU Elaine A. & Kenneth G. Langone Medical Center

Clients

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

Key Stats and Financials As of 2018
Market Capitalization
$215M
Total Enterprise Value
$57.6M
Earnings Per Share
$-1.7
Revenue
$3.6M
Net Profit
$-74.2M
EBITDA
$-74.6M
EBITDAMargin
-2,074.35%
Total Debt
$0
Total Equity
$92.2M
Enterprise Value Sales
16.03x
TEVNet Income
-0.78x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
61.78%
Five Year Compounded Annual Growth Rate Of Revenue
20.69%
Investors
Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Competitors
Bausch Health Cos., Inc. Pharmaceuticals - Laval, QC

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Allergan Plc Pharmaceuticals - Dublin, DU

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Nestlé SA Food - Vevey, VD

Nestle is ...the world's leading nutrition, health and wellness company. Our mission of "Good Food, Good Life" is to provide consumers with the best tasting, most nutritious choices in a wide range of food and beverage categories and eating occasions, from morning to night.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Foamix Pharmaceuticals Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Foamix Pharmaceuticals Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Foamix Pharmaceuticals Ltd..